Upsher-Smith Expands Haloperidol Product Family to Include Unit Dose Tablets

 // News

November 7  

MAPLE GROVE, Minn., Nov. 7, 2022 /PRNewswire/ — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has extended its line of Haloperidol Tablets, USP and is now offering unit dose packaging in 1 mg, 5 mg, and 10 mg strengths. The new packaging aims to expand supply options for dispensing pharmacies that utilize unit-dose packaged products. Upsher-Smith’s Haloperidol Tablets are also available in bottles of 100 tablets in 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg strengths. Haloperidol Tablets are a generic version of the brand product, Haldol® Tablets*.

The haloperidol unit-dose tablet market had U.S. sales of approximately $9 million for the 12 months ending July 2022 according to IQVIA.

Product Information

ProductStrengthNDC #Package Size
Haloperidol Tablets, USP1 mg0832-1520-01100-count UD
Haloperidol Tablets, USP5 mg0832-1540-01100-count UD
Haloperidol Tablets, USP10 mg0832-1550-01100-count UD

For questions about ordering, please call Upsher-Smith at 1-800-654-2299.

Please refer to the full Prescribing Information, including Boxed Warning for Haloperidol Tablets, USP here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting

About Upsher-Smith

 Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit

*Haldol is a registered trademark of Johnson & Johnson Corp; Haldol Tablets have been discontinued.

Success message!
Warning message!
Error message!